Diabetes Drug Designer to Speak on the Development Process

Daniel M. Drucker, MD

/kidneynews/8_10_11/34/graphic/34f1.jpg

An endocrinologist whose research has led to new treatments for diabetes will share insights from this work in a state-of-the-art lecture on Sunday, Nov. 20, entitled “Enteroendocrine Physiology Informs Drug Design for Type 2 Diabetes and Obesity.”6

Daniel M. Drucker, MD, is a senior scientist at the Lunenfeld-Tanenbaum Research Institute at Mt. Sinai Hospital and a professor of medicine at the University of Toronto.

A pioneer in diabetes treatment, Dr. Drucker’s work has provided important insights leading to the development of new drugs for the treatment of type 2 diabetes. His lab carried out the basic science supporting the development of two new classes of therapies for type 2 diabetes and a new therapy for patients with short bowel syndrome requiring parenteral nutrition. His research also shows tremendous promise for the treatment of obesity.

“My laboratory studies the molecular biology, physiology, and mechanism(s) of action of peptide hormones, and their G-protein-coupled receptors. We are particularly interested in the translational relevance of these peptidergic networks for the treatment of human metabolic disorders, and the emphasis in our laboratory is on translational science with therapeutic potential,” Dr. Drucker says. The lab’s focus is the family of hormones produced in the pancreas, gastrointestinal tract, and brain that control blood glucose and insulin secretion as well as regulate appetite, nutrient absorption, and the conversion of those nutrients to energy.

His team’s contributions to this field are reflected by several hundred publications, more than 40,000 citations of those publications, and 33 US patents covering various therapeutic aspects of peptide hormone action. Dr. Drucker’s lab is internationally known not only for its research, but also for pursuing the clinical relevance of scientific breakthroughs.

Dr. Drucker has served on the editorial boards of the American Journal of Physiology-Endocrinology and Metabolism and Endocrine Reviews. He is currently on the boards of Nature Reviews Endocrinology, Gastroenterology, and Diabetes, and is associate editor of Endocrinology.

He has received an array of international awards, including the Clinical Investigator Award from the Endocrine Society, the Oon International Award for Preventive Medicine from the Cambridge University School of Medicine in the UK, the Banting Medal for Scientific Achievement from the American Diabetes Association, the Manpei Suzuki International Prize for Diabetes Research from the Manpei Suzuki Foundation in Japan, and the Canadian Diabetes Association Outstanding Young Scientist Award.

Dr. Drucker trained in internal medicine and endocrinology at the Johns Hopkins Hospital in Baltimore and Toronto General Hospital. He completed a research fellowship in molecular endocrinology at Massachusetts General Hospital. He established his own laboratory research program in 1987 in Toronto.

October/November 2016  (Vol 8, Issue 10/11)